CTLA4 and melanoma: This synergy of anti-CTLA-4 or anti-PD-L1 with a range of RT doses and fractionations has been demonstrated in immune-competent mouse models of lung, breast, melanoma, and colorectal cancers [11,12,14,15,16,17,18].